| __timestamp | Dynavax Technologies Corporation | MannKind Corporation |
|---|---|---|
| Wednesday, January 1, 2014 | 17763000 | 79383000 |
| Thursday, January 1, 2015 | 22180000 | 108402000 |
| Friday, January 1, 2016 | 37257000 | 46928000 |
| Sunday, January 1, 2017 | 27367000 | 74959000 |
| Monday, January 1, 2018 | 64770000 | 79716000 |
| Tuesday, January 1, 2019 | 74986000 | 74669000 |
| Wednesday, January 1, 2020 | 79256000 | 59040000 |
| Friday, January 1, 2021 | 100156000 | 77417000 |
| Saturday, January 1, 2022 | 131408000 | 91473000 |
| Sunday, January 1, 2023 | 152946000 | 94314000 |
In pursuit of knowledge
In the dynamic world of biotechnology, understanding financial trends is crucial. Over the past decade, MannKind Corporation and Dynavax Technologies Corporation have showcased distinct patterns in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Dynavax's SG&A expenses surged by an impressive 760%, reflecting its aggressive expansion and strategic investments. In contrast, MannKind's expenses grew by a more modest 19%, indicating a steady, controlled approach.
These trends offer a window into each company's strategic priorities and market positioning, providing valuable insights for investors and industry analysts alike.
Who Optimizes SG&A Costs Better? Novo Nordisk A/S or MannKind Corporation
SG&A Efficiency Analysis: Comparing Viatris Inc. and MannKind Corporation
Dr. Reddy's Laboratories Limited and MannKind Corporation: SG&A Spending Patterns Compared
Who Optimizes SG&A Costs Better? Halozyme Therapeutics, Inc. or MannKind Corporation
Cost Management Insights: SG&A Expenses for Blueprint Medicines Corporation and Dynavax Technologies Corporation
Madrigal Pharmaceuticals, Inc. and Dynavax Technologies Corporation: SG&A Spending Patterns Compared
Cost Management Insights: SG&A Expenses for Alpine Immune Sciences, Inc. and MannKind Corporation
Cost Management Insights: SG&A Expenses for Ultragenyx Pharmaceutical Inc. and Dynavax Technologies Corporation
Selling, General, and Administrative Costs: Vericel Corporation vs Dynavax Technologies Corporation
Cost Management Insights: SG&A Expenses for Arrowhead Pharmaceuticals, Inc. and Dynavax Technologies Corporation
Breaking Down SG&A Expenses: MannKind Corporation vs Travere Therapeutics, Inc.
MannKind Corporation and Novavax, Inc.: SG&A Spending Patterns Compared